


*polpharma
biologics*

We exist to accelerate access
to biologic medicines



Follow us on
LinkedIn!



E office@polpharmabiologics.com
W www.polpharmabiologics.com

We care

Overview

Polpharma Biologics is a new-generation biosimilar company headquartered in Switzerland, focused on accelerating access to biologic medicines through agility, science and smart partnerships. As a partnership-based company, Polpharma Biologics builds on a strong legacy while embracing a lean and flexible operating model that enables cost-efficient development and global scalability.

With multiple biosimilars already approved and a pipeline of high-value assets - including first-to-launch opportunities - Polpharma Biologics is working with trusted partners to bring the next wave of affordable, high-quality biologics to patients worldwide.

Our mission

Polpharma Biologics combines deep scientific expertise with partner-enabled structure to deliver next-generation biosimilars - faster, smarter and more efficiently. Built on the foundation of Polpharma Biologics S.A, the company benefits from a proven track record in full lifecycle development, regulatory strategy and commercialization.

Driven by a mission to expand global access to biologics, Polpharma Biologics focuses on:

- **Deep expertise in every part of the value chain**, from cell line development through clinical and regulatory CMC up to final product supply.
- **Operational excellence**, with deep capabilities in program leadership, regulatory strategy, clinical oversight, CMC development, device development and quality.
- **Smart partnerships for collaborative growth**, working with leading global companies to drive commercialization of next-generation biosimilars.

With approved biosimilars already on the market and a robust pipeline of differentiated assets, Polpharma Biologics is well-positioned to shape the future of biosimilars. Strategic collaborations with industry leaders demonstrate the company's ability to co-create value and deliver at scale.

Our pipeline

| Candidate | Reference Drug | Therapeutic Area | Sub-Area / Key Indications | Preclinical | Clinical | Filing | Approval / commercial |
|--------------|----------------|------------------|--|-------------|------------|------------|-----------------------|
| Ranibizumab* | Lucentis® | Ophthalmology | Retinal diseases (AMD, DME, RVO) | ██████████ | ██████████ | ██████████ | ██████████ |
| Natalizumab | Tysabri® | Immunology | Multiple sclerosis (MS), Crohn's disease | ██████████ | ██████████ | ██████████ | ██████████ |
| Vedolizumab | Entyvio® | Immunology | Ulcerative colitis (UC), Crohn's disease (CD) | ██████████ | ██████████ | ██████████ | ██████████ |
| Ocrelizumab | Ocrevus® | Immunology | Multiple sclerosis (primary progressive, relapsing-remitting) (PPMS) | ██████████ | ██████████ | ██████████ | ██████████ |
| Guselkumab | Tremfya® | Immunology | Plaque psoriasis, psoriatic arthritis (PsA) | ██████████ | ██████████ | ██████████ | ██████████ |
| PB020 | undisclosed | Hematology | n.a. | ██████████ | ██████████ | ██████████ | ██████████ |
| PBX-001 | undisclosed | Hematology | n.a. | ██████████ | ██████████ | ██████████ | ██████████ |
| PB022 | undisclosed | Immunology | n.a. | ██████████ | ██████████ | ██████████ | ██████████ |
| PBX-002 | undisclosed | Immunology | n.a. | ██████████ | ██████████ | ██████████ | ██████████ |
| PBX-003 | undisclosed | Immunology | n.a. | ██████████ | ██████████ | ██████████ | ██████████ |

* via Bioeq AG

As a team of experienced biosimilar professionals, we lead with trust, act with drive and grow with purpose — always caring about the science, partnerships and patients that define our impact. Because at Polpharma Biologics, WE CARE.

Let's collaborate driving smarter, faster access to next-generation biosimilars.

